论文部分内容阅读
目的:探讨化疗前食管癌组织中ERCC1mRNA水平对CDDP/5- FU化疗疗效的预测价值。方法:采用半定量RT PCR检测 20例初治食管癌患者化疗前癌组织中ERCC1mRNA水平。患者接受 2周期CDDP/5- FU化疗后,分析化疗疗效与化疗前ERCC1mRNA水平的关系。结果:化疗前癌组织中ERCC1mRNA水平中位值 0. 956。11例化疗有效的ERCC1mRNA水平均值为 0. 799, 9例化疗无效者为 1. 147,差异具有统计学意义(P<0. 05),化疗前食管癌组织中ERCC1mRNA水平与化疗疗效呈负相关(rs=-0. 515, P=0. 02)。ERCC1mRNA高、低水平组患者的年龄、性别、病理类型、分化程度、TNM分期及化疗疗效间差异均无统计学意义 (P>0. 05)。结论:化疗前食管癌组织中ERCC1mRNA水平对CDDP/5 Fu化疗疗效的预测价值,值得扩大样本进一步研究。
Objective: To investigate the predictive value of ERCC1 mRNA level in the treatment of CDDP / 5-FU chemotherapy before chemotherapy. Methods: The level of ERCC1 mRNA in 20 patients with newly diagnosed esophageal cancer before chemotherapy was detected by semi-quantitative RT-PCR. After receiving 2 cycles of CDDP / 5-FU chemotherapy, patients were analyzed for their relationship to the level of ERCC1 mRNA before chemotherapy. Results: The median level of ERCC1 mRNA in pre-chemotherapy cancer tissue was 0.956.11 The mean ERCC1 mRNA level in chemotherapy was 0. 799, and 9 cases of ineffective chemotherapy were 1.147, the difference was statistically significant (P0.05 ). The level of ERCC1 mRNA in esophageal cancer before chemotherapy was negatively correlated with the efficacy of chemotherapy (rs = -0.515, P = .02). There was no significant difference in the age, sex, pathological type, differentiation degree, TNM staging and chemotherapy efficacy of ERCC1mRNA between high and low ERCC1mRNA group (P> 0.05). Conclusion: The predictive value of ERCC1 mRNA level in the chemosensitivity of esophageal carcinoma tissue before and after chemotherapy with CDDP / 5 Fu is worth further exploration.